SPX4,050.34-26.23 -0.64%
DIA343.15-1.27 -0.37%
IXIC11,384.60-97.85 -0.85%

Morgan Stanley Maintains Overweight Rating for IDEXX Laboratories: Here's What You Need To Know

Benzinga · 11/15/2022 12:00

Morgan Stanley has decided to maintain its Overweight rating of IDEXX Laboratories (NASDAQ:IDXX) and lower its price target from $573.00 to $543.00.

Shares of IDEXX Laboratories are trading up 2.16% over the last 24 hours, at $437.27 per share.

A move to $543.00 would account for a 24.18% increase from the current share price.

About IDEXX Laboratories

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.